Disclosure of the total number of voting rights and the number of shares in the capital as of November 30, 2021


Pursuant to Articles L-223-8 II of the Commercial Code and 223-16 of the AMF General Regulations.

SOPHIA ANTIPOLIS, France, December 06, 2021– (BUSINESS WIRE) – Regulatory news:

Médiane Technologies (Paris: ALMDT):

Total number of shares


Number of actual voting rights *
(excluding own shares **)


Theoretical number of voting rights *
(including own shares **)


Class E preferred shares are non-voting

(**) in application of article 223-11 of the AMF general regulations About Median Technologies:

Median Technologies provides innovative imaging solutions and services to advance healthcare for all. We leverage the power of phenomenal imagery to provide insight into new therapies and treatment strategies. Our unique solutions for the analysis and management of medical images in oncology trials and iBiopsy® for imaging phenotyping, along with our global team of experts, are advancing the development of new drugs and diagnostic tools to monitor disease and assess response to treatment. Median Technologies supports biopharmaceutical sponsors and healthcare professionals around the world to quickly and accurately deliver new treatments to patients in need. This is how we help create a healthier world.

Founded in 2002, based in Sophia-Antipolis, France, with a subsidiary in the United States and another in Shanghai, Median has received the “Innovative Company” label by BPI France and is listed on the Euronext Growth market (ISIN: FR0011049824 , ticker: ALMDT). Median is eligible for PEA-PME, is listed on the Enternext® PEA-PME 150 index and has obtained the Euronext European Rising Tech label. For more information: www.mediantechnologies.com See the source version on businesswire.com:


Mid-range technologies
Emmanuelle Leygues
Head of corporate communication and marketing
+33 6 10 93 58 88

Press – ALIZE RP
Caroline carmagnol
+33 6 64 18 99 59

Investors – ACTIFIN
Ghislaine Gasparetto
+33 1 56 88 11 11



Comments are closed.